Loading...
ALPS Medical Breakthroughs ETF
SBIO•AMEX
Financial ServicesAsset Management
$29.03
$-0.11(-0.38%)
ALPS Medical Breakthroughs ETF (SBIO) Stock Overview
Explore ALPS Medical Breakthroughs ETF’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for SBIOStats details for SBIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for SBIOAnalyst Recommendations details for SBIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Founded
2014